NATURE TECHNOLOGY CORPORATION

Company Information

Company Name
NATURE TECHNOLOGY CORPORATION
Address
4701 INNOVATION DRIVE
LINCOLN, NE, 68521-
Phone
n/a
URL
n/a
DUNS
7588486
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,162,204.00
7
SBIR Phase II
$1,740,035.00
2
Chart code to be here

Award List

  1. Promoter Rescue Vectors

    Amount: $142,017.00

    DESCRIPTION (provided by applicant): Mouse VL30 (retrotransposon) long terminal repeats (LTRs) are a potential source of tissue-specific transcriptional promoters that can be used to deliver and expre ...

    SBIR Phase I 2003 Department of Health and Human Services
  2. Chimeric enzyme for host nucleic acid autohydrolysis

    Amount: $143,800.00

    DESCRIPTION (provided by applicant): DNA vaccines and gene medicines are emerging as an important new class of pharmaceuticals that are derived from bacterial plasmids. For use in humans, plasmid D ...

    SBIR Phase I 2004 Department of Health and Human Services
  3. Chimeric enzyme for nucleic acid autohydrolysis

    Amount: $819,371.00

    DESCRIPTION (provided by applicant): DNA vaccines and gene medicines, derived from bacterial plasmids, are emerging as an important new class of pharmaceuticals. DNA molecules made strictly by rationa ...

    SBIR Phase II 2006 Department of Health and Human Services
  4. Antisense inhibitors for enhanced plasmid production

    Amount: $136,195.00

    DESCRIPTION (provided by applicant): Large scale manufacture of plasmid DNA is becoming increasingly important as the next generation of biotechnology products (gene medicines and DNA vaccines) make ...

    SBIR Phase I 2005 Department of Health and Human Services
  5. GENE SELF ASSEMBLY TECHNOLOGY

    Amount: $139,700.00

    N/A

    SBIR Phase I 1998 Department of Health and Human Services
  6. eukaryotic expression vectors resistant to transgene silencing

    Amount: $145,542.00

    DESCRIPTION (provided by applicant): Eukaryotic expression vectors are utilized for various biomedical applications including protein production, gene therapy and gene vaccination. A key barrier is th ...

    SBIR Phase I 2007 Department of Health and Human Services
  7. Rapid deployment DNA vaccine for pandemic influenza

    Amount: $207,016.00

    DESCRIPTION (provided by applicant): DNA-only vaccination would significantly enhance the rapid deployment utility of DNA vaccines for pandemic application (development times for DNA vaccines are sign ...

    SBIR Phase I 2007 Department of Health and Human Services
  8. eukaryotic expression vectors resistant to transgene silencing

    Amount: $920,664.00

    DESCRIPTION (provided by applicant): Plasmid-directed gene expression is now near the efficacy barrier that to date has prevented commercialization of plasmid-based therapies for human health applicat ...

    SBIR Phase II 2011 Department of Health and Human Services
  9. Improving Obesity Outcomes Through Interactive Web-Based Clinical Skills Training

    Amount: $247,934.00

    DESCRIPTION (provided by applicant): To commercialize non-viral gene medicines, it is critical that both vector potency (i.e. therapeutic transgene expression levels) and the duration of the therapeut ...

    SBIR Phase I 2013 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government